MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1111/dom.71061

Медицинская библиотека · Diabetes, obesity & metabolism · 2026

Efficacy and Safety of Tubeless Hybrid Closed-Loop Systems in Type 1 Diabetes: A Meta-Analysis of Randomized Controlled Trials.

Lei Mengyun, Lin Qiongyan, Zhou Yongwen, Ni Ying, Lin Ziqing, Ling Ping, Dai Zhe, Tang Jun, Yan Jinhua

СтатьяМетаанализПеревод пока не подготовлен

Аннотация

OBJECTIVE

To evaluate the efficacy and safety of tubeless hybrid closed-loop (HCL) systems in type 1 diabetes (T1D).

METHODS

We searched Web of Science, PubMed, Scopus, and Embase from inception to April 1st, 2026 for randomized controlled trials (RCTs) comparing tubeless HCL systems with standard care (SC; sensor-augmented pumps [SAP] or multiple daily injections [MDI] + continuous glucose monitoring [CGM]). Primary efficacy outcomes were time in range of 3.9-10.0 mmol/L (TIR) and glycated haemoglobin (HbA1c). Secondary efficacy outcomes included time above range (TAR10.0, TAR13.9), time below range (TBR3.9, TBR3.0), and coefficient of variability (CV). Safety outcomes included severe hypoglycaemia (SH) and diabetic ketoacidosis (DKA) risks. Random- or fixed-effects models were used as appropriate.

RESULTS

Four RCTs involving 514 participants were included. The mean age was 32.3 ± 15.7 years, with a mean T1D duration of 14.7 ± 11.1 years, and with mean baseline HbA1c 8.0% ± 1.0%. Three studies compared tubeless HCL with SAP, and one with MDI + CGM. Compared with SC, tubeless HCL improved TIR (MD = 15.31%, 95% CI [7.67%, 22.95%], I 2 = 95%, p < 0.001) and HbA1c (MD = -0.46%, 95% CI [-0.79%, -0.14%], I 2 = 91%, p = 0.005). Lower levels of TAR (TAR10.0, TAR13.9), TBR3.9 and CV were also observed (all p < 0.001) in tubeless HCL group. No significant differences were observed in TBR3.0 (MD = -0.06%, 95% CI [-0.17%, 0.06%], I 2 = 71%, p = 0.35) and insulin dose. DKA and SH events were rare in both groups.

CONCLUSIONS

The available evidence suggests that tubeless HCL systems may improve glycaemic control without increasing insulin dose or short-term safety risks. Head-to-head trials using identical algorithms are needed to isolate form-factor-specific effects.

Для цитирования: Lei Mengyun, Lin Qiongyan, Zhou Yongwen, Ni Ying, Lin Ziqing, Ling Ping, Dai Zhe, Tang Jun, Yan Jinhua. Efficacy and Safety of Tubeless Hybrid Closed-Loop Systems in Type 1 Diabetes: A Meta-Analysis of Randomized Controlled Trials.. Diabetes, obesity & metabolism. 2026. DOI: 10.1111/dom.71061.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.